amifostine anhydrous and carboplatin

amifostine anhydrous has been researched along with carboplatin in 65 studies

Research

Studies (65)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	29 (44.62)	18.2507
2000's	32 (49.23)	29.6817
2010's	4 (6.15)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Peters, GJ; Treskes, M; van der Vijgh, WJ; van der Wilt, CL; van Laar, JA	1
Holwerda, U; Klein, I; Pinedo, HM; Treskes, M; van der Vijgh, WJ	1
Boven, E; Cloos, J; Peters, GJ; Pinedo, HM; Treskes, M; van de Loosdrecht, AA; van der Vijgh, WJ; Wijffels, JF	1
Treskes, M; van der Vijgh, WJ	1
Adelstein, D; Bauer, L; Budd, GT; Bukowski, RM; Ganapathi, R; Gibson, V; McLain, D; Murthy, S; Sergi, J; Weick, J	1
Anderson, H; Betticher, DC; Meely, K; Oster, W; Ranson, M; Thatcher, N	1
Borsi, JD; Csaki, C; Ferencz, T; Oster, W	1
Budd, GT	1
Korst, AE; van der Vijgh, WJ	1
Budd, GT; Bukowski, RM; Ganapathi, R; Murthy, S	1
Boven, E; Fichtinger-Schepman, AM; Korst, AE; van der Sterre, ML; van der Vijgh, WJ	1
Adelstein, DJ; Budd, GT; Bukowski, RM; Capizzi, R; Ganapathi, R; McLain, D; Olencki, T; Pelley, R; Petrus, J; Zhang, J	1
Eeltink, CM; Korst, AE; van der Vijgh, WJ; Vermorken, JB	1
Mohamed, AK; Philips, RH; Radzi, A; Selvaratnam, G	1
Büntzel, J; Glatzel, M; Küttner, K; Schuth, J	1
Büntzel, J; Fröhlich, D; Glatzel, M; Küttner, K	1
Battaglia, A; Bonanno, G; Fattorossi, A; Leone, G; Mancuso, S; Menichella, G; Panici, PB; Perillo, A; Pierelli, L; Scambia, G	1
Eeltink, CM; Fichtinger-Schepman, AM; Korst, AE; van der Sterre, ML; van der Vijgh, WJ; Vermorken, JB	1
Armenaki, A; Frangiadaki, C; Georgoulias, V; Giatromanolaki, A; Helidonis, E; Koukourakis, MI; Koumandakis, E; Kranidis, A; Stefanaki, I	1
Bonnotte, B; Chauffert, B; Chvetzoff, G	1
Bruchelt, G; Eisenbeiss, F; Klingebiel, T; Meissner, T; Niethammer, D; Renner, S	1
Budd, GT; Bukowski, RM; Ganapathi, R; McLain, D; Snyder, J; Wood, L	1
Belani, CP; Selvaggi, G	1
Sauer, R; Strnad, V	1
Kimmig, B; Schultze, J	1
Engel, A; Feyerabend, T; Marx, M; Richter, E; Vacha, P	1
Fietkau, R; Hamann, D; Mücke, R; Peters, K; Ziegler, PG	1
Altmann, S; Hoffmanns, H	1
Büntzel, J; Fröhlich, D; Glatzel, M; Küttner, K; Schuth, J; Weinaug, R	1
Bahlitzanakis, N; Froudarakis, M; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Retalis, G	1
Brown, JM; Gurney, EM; Hepburn, PM; Johnson, PW; Muers, MF; Napp, VV; Peake, MD; Poulter, KM	1
Ayash, LJ; Cronin, S; Raith, C; Ratanatharathorn, V; Uberti, JP	1
Bennett, CL; Buntzel, J; Glatzel, M; Lane, D; Stinson, T	1
Blohmer, JU; Böhmer, D; Elling, D; Ernhardt, B; Lichtenegger, W; Paepke, S; Sehouli, J	1
Berthold, F; Fichtner, I; Fulda, S; Hero, B	1
Baruchel, S; Fouladi, M; Gammon, J; Grant, R; Greenberg, ML; Klein, J; Koren, G; Stempak, D	1
Antonadou, D; Pepelassi, M; Puglisi, M; Synodinou, M; Throuvalas, N	1
Büntzel, J; Fröhlich, D; Glatzel, M; Kuttner, K; Weinaug, R	1
Axelrod, RS; Chapman, AE; Curran, WJ; Deshields, M; Friedland, DP; Grubbs, S; Hauck, W; Rose, LJ; Werner-Wasik, M	1
Boven, E; Erkelens, CA; Hausheer, FH; Hulscher, TM; Pinedo, HM; van der Vijgh, WJ; Verschraagen, M	1
Senzer, N	1
Ang, P; Ang, PT; Chew, L; Fong, KW; Foo, KF; Lee, KM; Leong, SS; Lim, SH; Ong, YK; Tai, BC; Tan, EH; Wee, J; Wilder-Smith, E	1
Fehlauer, F; Feyerabend, T; Hinke, A; Mahlmann, B; Marx, M; Richter, E; Sommer, K; Vacha, P	1
Biamonte, R; Di Vagno, G; Ferrandina, G; Ferrau', F; Gadducci, A; Greggi, S; Lorusso, D; Manzione, L; Pignata, S; Scambia, G; Tateo, S	1
Antonadou, D; Bolanos, N; Petridis, A; Sagriotis, A; Synodinou, M; Throuvalas, N	1
Baran, I; Coskun, H; Demiray, M; Evrensel, T; Gonullu, G; Kanat, O; Kurt, E; Manavoglu, O; Turan, OF; Zarifoglu, M	1
Antonadou, D; Bolanos, N; Petridis, A; Sagriotis, A; Synodinou, M; Throuvalas, N; Veslemes, M	1
Costello, R; Haddad, R; Posner, M; Weeks, L; Wirth, L	1
Alberts, DS; Hallum, AV; Hannigan, EV; Jiang, C; Liu, PY; Markman, M; Scudder, SA; Smith, GB; Smith, HO; Wilczynski, SP	1
Banglore, M; Jaboin, J; Ord, R; Suntharalingam, M; Taylor, R; Van Echo, D; Wolf, J	1
Langer, C; Movsas, B; Werner-Wasik, M	1
Boezen, HM; Bos, AM; de Graaf, H; de Swart, CA; De Vos, FY; de Vries, EG; Schaapveld, M; van der Zee, AG; Willemse, PH	1
Axelrod, R; Byhardt, R; Komaki, R; Langer, C; Machtay, M; Movsas, B; Nicolaou, N; Sarna, L; Scott, C; Smith, C; Wasserman, T; Werner-Wasik, M	1
Burges, A; du Bois, A; Heilmann, V; Hilpert, F; Richter, B; Rossner, D; Späthe, K; Stähle, A; Tomé, O	1
Adamietz, IA; Buentzel, J; de Vries, A; Glatzel, M; Micke, O; Monnier, A	1
Aref, A; de Guzman, A; Leonard, R; Maria, V; Norales, G	1
Christie, D; Kennedy, T; Law, A; Pellitteri, P; Wood, C; Yumen, O	1
Cheerva, AC; Gross, TG; Kadota, RP; Levine, JE; Ozkaynak, MF; Richards, MK; Rozans, MK; Sahdev, I; Shaw, PJ	1
Byhardt, R; Komaki, R; Langer, C; Machtay, M; Movsas, B; Nicolaou, N; Sarna, L; Swann, S; Wasserman, T; Werner-Wasik, M	1
Allen, A; Braschayko, P; Burke, E; Costello, R; Flynn, J; Haddad, R; Li, Y; Mahadevan, A; Posner, M; Sonis, S; Tishler, RB; Wirth, L	1
Chang, KW; Chen, Z; Finegold, MJ; Katzenstein, HM; Krailo, M; London, WB; Malogolowkin, M; Pappo, A; Reynolds, M; Rowland, J	1
Albain, K; Bae, K; Curran, WJ; Gore, EM; Komaki, R; Machtay, M; Movsas, B; Paulus, R; Sause, WT	1
van As, JW; van Dalen, EC; van den Berg, H	2
Axelrod, RS; Bradley, JD; Buyyounouski, MK; Komaki, R; Langer, C; Lawrence, YR; Machtay, M; Movsas, B; Paulus, R; Smith, C; Wasserman, T; Werner-Wasik, M	1

Reviews

11 review(s) available for amifostine anhydrous and carboplatin

Article	Year
WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach. Cancer chemotherapy and pharmacology, 1993, Volume: 33, Issue:2 Topics: Amifostine; Animals; Bone Marrow Diseases; Carboplatin; Cisplatin; Ear Diseases; Gastrointestinal Diseases; Humans; Kidney Failure, Chronic; Nervous System Diseases	1993
Amifostine and chemotherapy-related thrombocytopenia. Seminars in oncology, 1996, Volume: 23, Issue:4 Suppl 8 Topics: Amifostine; Antineoplastic Agents; Carboplatin; Drug Interactions; Drug Therapy, Combination; Humans; Neoplasms; Thrombocytopenia	1996
Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo. European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A Suppl 4 Topics: Amifostine; Animals; Antineoplastic Agents; Carboplatin; Cisplatin; DNA Adducts; Drug Administration Schedule; Drug Interactions; Female; Mice; Ovarian Neoplasms	1996
Clinical effects of amifostine (Ethyol) in patients treated with carboplatin. European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A Suppl 4 Topics: Amifostine; Animals; Antineoplastic Agents; Carboplatin; Clinical Trials as Topic; Humans; Mice; Neoplasms; Thrombocytopenia	1996
Adverse effects of cytotoxics-platinum agents. Adverse drug reactions and toxicological reviews, 1997, Volume: 16, Issue:3 Topics: Amifostine; Antineoplastic Agents; Carboplatin; Cisplatin; Humans; Kidney Diseases; Neoplasms; Peripheral Nervous System Diseases; Protective Agents	1997
[Anticancer chemotherapy. Prevention of toxicity]. Presse medicale (Paris, France : 1983), 1998, Dec-12, Volume: 27, Issue:39 Topics: Amifostine; Antidotes; Antineoplastic Agents; Carboplatin; Cisplatin; Clinical Protocols; Female; Heart; Humans; Male; Neoplasms; Protective Agents	1998
Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine. Seminars in oncology, 1999, Volume: 26, Issue:2 Suppl 7 Topics: Amifostine; Antineoplastic Agents; Carboplatin; Clinical Trials as Topic; Colony-Stimulating Factors; Cytoprotection; Humans; Platelet Transfusion; Protective Agents; Thrombocytopenia; Thrombopoietin	1999
Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine. Seminars in oncology, 1999, Volume: 26, Issue:2 Suppl 7 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytoprotection; Humans; Lung Neoplasms; Nervous System Diseases; Paclitaxel; Protective Agents; Randomized Controlled Trials as Topic	1999
Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy w Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 18 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Follow-Up Studies; Humans; Injections, Subcutaneous; Lung Neoplasms; Mucous Membrane; Radiation-Protective Agents	2004
Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. The Cochrane database of systematic reviews, 2012, May-16, Issue:5 Topics: Adolescent; Amifostine; Antineoplastic Agents; Bone Neoplasms; Carboplatin; Child; Child, Preschool; Cisplatin; Controlled Clinical Trials as Topic; Hearing Loss; Hepatoblastoma; Humans; Infant; Infant, Newborn; Liver Neoplasms; Neoplasms; Osteosarcoma; Protective Agents; Randomized Controlled Trials as Topic; Young Adult	2012
Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. The Cochrane database of systematic reviews, 2014, Jul-01, Issue:7 Topics: Adolescent; Amifostine; Antineoplastic Agents; Bone Neoplasms; Carboplatin; Child; Child, Preschool; Cisplatin; Controlled Clinical Trials as Topic; Hearing Loss; Hepatoblastoma; Humans; Infant; Infant, Newborn; Liver Neoplasms; Neoplasms; Osteosarcoma; Protective Agents; Randomized Controlled Trials as Topic; Young Adult	2014

Trials

41 trial(s) available for amifostine anhydrous and carboplatin

Article	Year
Phase I study of WR-2721 and carboplatin. European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:8 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Platinum; Thrombocytopenia	1993
Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study. British journal of cancer, 1995, Volume: 72, Issue:6 Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Bone Marrow Diseases; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiation-Protective Agents	1995
Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer, 1997, Sep-15, Volume: 80, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents; Bone Marrow; Carboplatin; Female; Humans; Male; Middle Aged; Neoplasms; Neutrophils; Platelet Count; Thrombocytopenia; Treatment Outcome	1997
Pharmacokinetics of amifostine and its metabolites in patients. European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:9 Topics: Adult; Amifostine; Antineoplastic Agents; Carboplatin; Cisplatin; Disulfides; Drug Therapy, Combination; Female; Half-Life; Humans; Male; Mercaptoethylamines; Middle Aged	1997
Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1998, Volume: 6, Issue:2 Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Radiation-Protective Agents; Treatment Outcome	1998
Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:5 Topics: Adult; Aged; Amifostine; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Cytoprotection; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Radiation-Protective Agents	1998
Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:5 Topics: Amifostine; Animals; Antineoplastic Agents; Carboplatin; Dose-Response Relationship, Drug; Half-Life; Kidney; Kidney Function Tests; Metabolic Clearance Rate; Mice; Mice, Nude; Neoplasms	1997
Fractionated carboplatin radiosensitization: a phase I dose-escalation study. American journal of clinical oncology, 1998, Volume: 21, Issue:6 Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Pelvic Neoplasms; Radiation-Protective Agents; Radiation-Sensitizing Agents; Recombinant Proteins	1998
[Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1999, Volume: 175 Suppl 4 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Karnofsky Performance Status; Male; Middle Aged; Postoperative Care; Prospective Studies; Radiation-Protective Agents; Radiotherapy; Radiotherapy Dosage; Salivary Glands; Stomatitis; Time Factors; Xerostomia	1999
Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1999, Volume: 175 Suppl 4 Topics: Adolescent; Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Leukocyte Count; Middle Aged; Platelet Count; Prognosis; Radiation-Protective Agents; Radiodermatitis; Radionuclide Imaging; Radiotherapy; Radiotherapy Dosage; Salivary Glands; Skin Temperature; Time Factors	1999
[Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1999, Volume: 175 Suppl 4 Topics: Adult; Aged; Amifostine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cytoprotection; Fluorouracil; Head and Neck Neoplasms; Humans; Middle Aged; Mouth Mucosa; Postoperative Care; Preoperative Care; Radiation-Protective Agents; Radiotherapy; Radiotherapy Dosage; Retrospective Studies; Stomatitis; Time Factors	1999
Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer. Medical oncology (Northwood, London, England), 2000, Volume: 17, Issue:2 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Docetaxel; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm, Residual; Neoplasms; Paclitaxel; Taxoids	2000
A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer. British journal of cancer, 2001, Jan-05, Volume: 84, Issue:1 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Thrombocytopenia	2001
Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer investigation, 2001, Volume: 19, Issue:2 Topics: Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Costs and Cost Analysis; Female; Germany; Head and Neck Neoplasms; Hospitalization; Humans; Male; Middle Aged; Radiation-Protective Agents; Radiotherapy; Radiotherapy Dosage; Salivary Gland Neoplasms; Treatment Outcome	2001
[Adjuvant chemotherapy of cervix carcinoma--results of a phase II study]. Zentralblatt fur Gynakologie, 2001, Volume: 123, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenosquamous; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hysterectomy; Ifosfamide; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Uterine Cervical Neoplasms	2001
Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients. Medical and pediatric oncology, 2001, Volume: 36, Issue:1 Topics: Adolescent; Amifostine; Animals; Antineoplastic Agents; Bone Marrow Diseases; Carboplatin; Cell Division; Child; Child, Preschool; Cisplatin; Cross-Over Studies; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Etoposide; Humans; Ifosfamide; Mercaptoethylamines; Mice; Mice, Nude; Neuroblastoma; Neutropenia; Prodrugs; Safety; Thrombocytopenia; Treatment Failure; Tumor Cells, Cultured; Vincristine; Vomiting; Xenograft Model Antitumor Assays	2001
Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. Cancer, 2001, Aug-15, Volume: 92, Issue:4 Topics: Adolescent; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Male; Mercaptoethylamines; Neoplasms; Treatment Failure	2001
Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. International journal of radiation oncology, biology, physics, 2002, Mar-01, Volume: 52, Issue:3 Topics: Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mouth Mucosa; Radiation Injuries; Radiation-Protective Agents; Stomatitis; Xerostomia	2002
Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in radiation oncology, 2002, Volume: 12, Issue:1 Suppl 1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amifostine; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Edema; Esophageal Stenosis; Female; Fibrosis; Follow-Up Studies; Humans; Male; Middle Aged; Pharyngeal Neoplasms; Radiation Injuries; Radiation-Protective Agents; Radiotherapy Dosage; Taste Disorders; Xerostomia	2002
Phase II: trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy. Seminars in radiation oncology, 2002, Volume: 12, Issue:1 Suppl 1 Topics: Acute Disease; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Esophagitis; Esophagus; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Radiation-Sensitizing Agents; Survival Rate	2002
A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 19 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Cytoprotection; Deoxycytidine; Esophagitis; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiation Injuries; Radiation-Protective Agents	2002
Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-01, Volume: 21, Issue:9 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Double-Blind Method; Esophagitis; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Radiation Injuries; Radiation-Protective Agents; Treatment Outcome	2003
Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2003, Volume: 179, Issue:6 Topics: Amifostine; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Mouth Mucosa; Neoplasm Staging; Patient Selection; Radiation-Protective Agents; Radiotherapy; Radiotherapy Dosage; Time Factors; Xerostomia	2003
Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:7 Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Erythrocyte Count; Female; Humans; Infusions, Intravenous; Middle Aged; Mouth Mucosa; Neutropenia; Ovarian Neoplasms; Paclitaxel; Radiation-Protective Agents; Stomatitis; Thrombocytopenia	2003
Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. International journal of radiation oncology, biology, physics, 2003, Oct-01, Volume: 57, Issue:2 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Paclitaxel; Radiation Injuries; Radiation Pneumonitis; Radiation-Protective Agents; Radiotherapy Dosage; Stomatitis; Treatment Outcome	2003
Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study. Medical oncology (Northwood, London, England), 2003, Volume: 20, Issue:3 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cytoprotection; Female; Heart Diseases; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Prospective Studies; Protective Agents	2003
Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer. Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18 Topics: Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation Injuries; Radiation Pneumonitis; Radiation-Protective Agents; Radiation-Sensitizing Agents	2003
Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Stomatitis; Xerostomia	2003
Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. Gynecologic oncology, 2005, Volume: 96, Issue:3 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel	2005
The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT). Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 18 Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mucous Membrane; Paclitaxel; Radiotherapy Dosage	2004
Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy w Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 18 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Follow-Up Studies; Humans; Injections, Subcutaneous; Lung Neoplasms; Mucous Membrane; Radiation-Protective Agents	2004
A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. Gynecologic oncology, 2005, Volume: 97, Issue:1 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Staging; Nervous System Diseases; Neuroprotective Agents; Neutropenia; Ovarian Neoplasms; Paclitaxel; Quality of Life	2005
Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Apr-01, Volume: 23, Issue:10 Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deglutition Disorders; Dose Fractionation, Radiation; Esophagitis; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Radiation Injuries; Radiation-Protective Agents; Survival Analysis; Treatment Outcome	2005
Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AG Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2005, Volume: 13, Issue:10 Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Humans; Neuroprotective Agents; Neurotoxicity Syndromes; Ovarian Neoplasms; Paclitaxel; Placebos; Radiation-Protective Agents	2005
Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. International journal of radiation oncology, biology, physics, 2006, Mar-01, Volume: 64, Issue:3 Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Disease Progression; Double-Blind Method; Female; Head and Neck Neoplasms; Humans; Injections, Intravenous; Male; Middle Aged; Radiation Injuries; Radiation-Protective Agents; Stomatitis; Survival Rate; Xerostomia	2006
Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck. International journal of radiation oncology, biology, physics, 2007, Dec-01, Volume: 69, Issue:5 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Injections, Subcutaneous; Male; Middle Aged; Mucositis; Paclitaxel; Prospective Studies; Radiation Injuries; Radiation-Protective Agents; Radiotherapy Dosage; Xerostomia	2007
A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study. Journal of pediatric hematology/oncology, 2008, Volume: 30, Issue:3 Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Carboplatin; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Etoposide; Feasibility Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hypocalcemia; Kidney Neoplasms; Melphalan; Neoplasms; Neuroblastoma; Pilot Projects; Recurrence; Risk Factors; Sarcoma; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Wilms Tumor	2008
Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer, 2009, Oct-01, Volume: 115, Issue:19 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Cytokines; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Injections, Subcutaneous; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Stomatitis; Survival Rate; Xerostomia	2009
Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group. Cancer, 2009, Dec-15, Volume: 115, Issue:24 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cisplatin; Disease-Free Survival; Female; Hearing Loss; Hepatoblastoma; Humans; Infant; Infant, Newborn; Male; Radiation-Protective Agents	2009
Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. International journal of radiation oncology, biology, physics, 2012, Jan-01, Volume: 82, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Radiotherapy Dosage; Relative Biological Effectiveness; Retrospective Studies; Survival Analysis; Treatment Failure; Vinblastine	2012
The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801. Lung cancer (Amsterdam, Netherlands), 2013, Volume: 80, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel	2013

Other Studies

14 other study(ies) available for amifostine anhydrous and carboplatin

Article	Year
Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil. Cancer chemotherapy and pharmacology, 1992, Volume: 31, Issue:2 Topics: Amifostine; Anemia; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Neoplasms; Female; Fluorouracil; Leukopenia; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Random Allocation; Thrombocytopenia; Weight Loss	1992
The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin. Biochemical pharmacology, 1991, Nov-06, Volume: 42, Issue:11 Topics: Amifostine; Carboplatin; Cisplatin; Drug Administration Schedule; Drug Interactions; Kinetics; Mercaptoethylamines; Radiation-Protective Agents	1991
Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:2 Topics: Amifostine; Animals; Bone Marrow; Carboplatin; Cell Division; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms	1994
Administration of Ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin. Anti-cancer drugs, 1996, Volume: 7, Issue:1 Topics: Amifostine; Antineoplastic Agents; Carboplatin; Cerebellar Neoplasms; Child; Humans; Male; Medulloblastoma; Neutropenia; Radiation-Protective Agents; Thrombocytopenia	1996
Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice. British journal of cancer, 1997, Volume: 75, Issue:10 Topics: Amifostine; Animals; Antineoplastic Agents; Body Temperature; Carboplatin; DNA Adducts; Drug Administration Schedule; Drug Synergism; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Platinum; Radiation-Protective Agents; Transplantation, Heterologous	1997
In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue. British journal of cancer, 1998, Volume: 78, Issue:8 Topics: Amifostine; Antigens, CD34; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Cell Cycle; Cell Division; Cells, Cultured; Docetaxel; Doxorubicin; Etoposide; Hematopoietic Stem Cells; Humans; Leukocytes, Mononuclear; Paclitaxel; Taxoids; Time Factors	1998
Isotachophoretic determination of phosphate splitting from Amifostine and p-nitrophenyl phosphate in serum and neuroblastoma cells. Journal of chromatography. A, 1999, Apr-09, Volume: 838, Issue:1-2 Topics: Amifostine; Carboplatin; Cell Division; Electrophoresis; Humans; Neuroblastoma; Nitrophenols; Organophosphorus Compounds; Phosphates; Phosphorylation; Sulfhydryl Compounds; Tumor Cells, Cultured	1999
[New data on cytoprotection in radiotherapy]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1999, Volume: 175 Suppl 4 Topics: Amifostine; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Cytoprotection; Double-Blind Method; Follow-Up Studies; Head and Neck Neoplasms; Humans; Pilot Projects; Placebos; Postoperative Care; Preoperative Care; Radiation-Protective Agents; Radiotherapy; Randomized Controlled Trials as Topic; Stomatitis; Time Factors; Xerostomia	1999
[Outcome of primary combined radio-chemotherapy in head and neck tumors with simultaneous salivary gland protection by amifostine]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1999, Volume: 175 Suppl 4 Topics: Amifostine; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Male; Middle Aged; Prospective Studies; Radiation-Protective Agents; Radionuclide Imaging; Radiotherapy Dosage; Salivary Glands; Time Factors; Treatment Outcome; Xerostomia	1999
[Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1999, Volume: 175 Suppl 4 Topics: Adult; Aged; Amifostine; Anemia; Antineoplastic Agents; Brachytherapy; Carboplatin; Combined Modality Therapy; Cytoprotection; Deglutition Disorders; Female; Head and Neck Neoplasms; Humans; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Postoperative Care; Radiation-Protective Agents; Radiotherapy; Radiotherapy Dosage; Stomatitis; Thrombocytopenia; Time Factors; Xerostomia	1999
Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation. Bone marrow transplantation, 2000, Volume: 26, Issue:11 Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Kidney Diseases; Male; Testicular Neoplasms; Transplantation Conditioning	2000
BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:8 Topics: Amifostine; Animals; Antineoplastic Agents; Carboplatin; Cell Division; Cisplatin; Drug Interactions; Female; Humans; Lethal Dose 50; Mesna; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Protective Agents; Radiation-Protective Agents; Transplantation, Heterologous; Weight Loss	2002
Amifostine-induced back pain: a case report. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2006, Feb-15, Volume: 63, Issue:4 Topics: Amifostine; Back Pain; Carboplatin; Humans; Male; Middle Aged; Neoplasms, Squamous Cell; Radiation-Protective Agents; Tongue Neoplasms; Xerostomia	2006
Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. International journal of radiation oncology, biology, physics, 2008, Dec-01, Volume: 72, Issue:5 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deglutition; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Quality of Life; Radiation-Protective Agents; Sexual Behavior; Socioeconomic Factors; Treatment Outcome; Weight Loss	2008